Table 1

Selected average parameters from pressure-volume loop study in vivo assessment of left ventricular function are expressed as mean ± SEM
Variables Control Dox Vitamin E Telmisartan P value
End-systolic Volume (uL) 43.64 ± 1.23 69.61 ± 2.36 51.34 ± 1.22 <0.05
End-diastolic Volume (uL) 69.61 ± 2.37 85.03 ± 3.53 63.21 ± 1.43 <0.05
End-systolic Pressure (mmHg) 70.57 ± 1.22 56.64 ± 6.76 64.65 ± 1.75 <0.05
End-diastolic Pressure (mmHg) 8.36 ± 1.19 3.42 ± 0.36 7.14 ± 1.54 <0.05
Ejection Fraction (%) 42.34 ± 3.21 17.35 ± 0.57 25.43 ± 1.21 <0.05
Cardiac Output (ml/min) 12.67 ± 1.26 6.03 ± 0.4 7.83 ± 1.17 <0.51
E MAX 21.38 ± 2.36 14.34 ± 1.32 16.43 ± 1. <0.51

P < 0.05, statistically differences between Dox treated only group and with Vitamin E, and Telmisartan treatment; (n = 8 per group).

Hadi et al.

Hadi et al. BMC Cardiovascular Disorders 2012 12:63   doi:10.1186/1471-2261-12-63

Open Data